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Research
AbstrACt
Objective This study aimed to assess the incidence and 
risk factors of treatment failure among HIV/AIDS-infected 
children who were on antiretroviral therapy (ART) in 
Amhara National Regional State, Ethiopia.
Methods A retrospective follow-up study was conducted 
from January 2010 to March 2016. A total of 824 children 
under the age of 15 who had started ART were included 
in the study. Data were collected from children’s medical 
charts and ART registration logbook using a standard 
checklist. A Weibull regression model was used to identify 
the risk factors of treatment failure. Adjusted HRs (AHRs) 
with 95% CIs were used to declare statistical significance.
results The mean (±SD) age of the children was 6.4±3.6 
years, with a median (IQR) follow-up of 30.5 (14.6–51.4) 
months. Sixty-three children (7.7%, 95% CI 5.8 to 9.5) 
developed treatment failure, 17 (27.0%) of whom were 
immunological and 46 (73.0%) were clinical failures. 
The incidence rate of treatment failure was 22.1/10 000 
person-months. The cumulative probability of failure was 
0.4, with 28 562.5 person-month observations. Lack of 
disclosure (AHR=4. 4, 95% CI 1.8 to 11.3), opportunistic 
infections during initiation of ART (AHR=2.3, 95% CI 1.3 to 
4.1) and prolonged follow-up (AHR=0.06, 95% CI 0.02 to 
0.18) were the main predictors of treatment failure.
Conclusion This study revealed that the incidence of 
treatment failure remains a significant public health 
concern in Ethiopia. Undisclosed HIV status to children, 
the presence of opportunistic infections during initiation of 
ART and prolonged follow-up were found to be the main 
predictors of treatment failure. Hence, early detection of 
treatment failure and further studies on viral monitoring 
need to be considered.
bACkgrOund
Globally, the HIV pandemic has affected over 
36.9 million people. Of these, 2.6 million 
were children under 15 years of age. About 
90% of new HIV infections among children 
and 150 000 (5.8%) of child death were in 
Sub-Saharan Africa.1 In Ethiopia, 134 586 
children were living with HIV/AIDS in 
2014.2 A previous report showed that one in 
four (25%) of the HIV-infected children die 
without treatment before their fifth birthday 
due to AIDS-related diseases.3 The incidence 
of HIV infection has been reduced, and 
AIDS-related deaths in Sub-Saharan Africa 
declined by 48% between 2004 and 20141 4 
due to the scale-up of antiretroviral therapy 
(ART).
Globally, a lot of progress has been made 
over the past few years towards the preven-
tion of the incidence and access to treat-
ment.2 Hence, globally, 32% of HIV-infected 
children were on ART; 41% of them were in 
Sub-Saharan Africa, while 23.5% lived in Ethi-
opia.1 5
The increment of the utilisation of ART 
raised the issue of drug resistance6 and subse-
quent treatment failure presenting as one 
or more of clinical, immunological or viro-
logical failure in middle-income and low-in-
come countries.6 The benefit of first-line 
strengths and limitations of this study
 ► The study included the  antiretroviral therapy cen-
tres of six public hospitals, along with prolonged 
follow-ups.
 ► Data were collected from routine medical care re-
cords and there were limited data on possible pre-
dictors of failure, such as laboratory assessment 
and prevention of maternal to child transmission.
 ► There might be an underestimation of treatment 
failure. Data mainly depended on clinical and immu-
nological criteria. Virological failure was not used to 
detect treatment failure.
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antiretroviral drugs (ARVs) could be greatly compro-
mised by ART failure in children.
The WHO recommended the use of regular virolog-
ical monitoring for both developed and resource-limited 
settings.7 Due to cost implications, currently clinical and 
immunological criteria are used to monitor treatment 
failure in resource-limited settings,8 although the WHO 
clinical and CD4 criteria have poor sensitivity and speci-
ficity in detecting virological failure.9–11
Treatment failure and drug toxicity are critical in the 
national ART programme. Public health leaders consider 
the availability of financial, human and other essential 
resources, as well as access for the most at-risk populations.12 
But treatment failures are not well-documented, while 
there is a large scale-up of ARV supplies in resource-lim-
ited countries like Ethiopia. Studies done in Africa showed 
that the rate of treatment failure among children was 
heterogeneous geographically. For example, 18.8% of chil-
dren in Nigeria13 and 26%–34% in Uganda14 15 reported 
treatment failure. Out of the 29% failure in Mozambique 
and Uganda, 46% and 53% were immunological and clin-
ical failures, respectively.16 In Thailand the regimen was 
changed in 17.1% of children due to treatment failure.17
A study conducted in Addis Ababa showed that 14.1% 
of children had treatment failure. Of these, 5.9% were 
clinical, 6.7% were immunological, and 1.5% were both 
clinical and immunological failures.18 In Adama 69.8% 
were switched to second-line treatment due to treatment 
failures.19 There has been limited evidence on the effects 
of clinical and sociodemographic factors on poor treat-
ment outcomes in the study setting.
This study investigated the incidence of treatment 
failure and risk factors among children below 15 years 
of age who were on ART in the public hospitals of the 
Amhara National Regional State.
MethOds
study design and setting
A retrospective follow-up study was conducted at six 
public hospitals, namely the University of Gondar 
Teaching Hospital, Debre Tabor Hospital, Felege Hiwot 
Specialized Hospital, Debre Markos Hospital, Dessie 
Referral Hospital and Debre Berhan Referral Hospital, 
from January 2010 to March 2016.
Amhara National Regional State is the second largest 
region in Ethiopia, with great climatic, geographical and 
cultural diversity. According to the Central Statistical 
Agency of Ethiopia, Health and Health Related Indica-
tors published by Federal Ministry of Health (FMoH), 
Amhara has 19 hospitals, 520 health centres and 2941 
health posts. The Amhara National Regional State has an 
estimated population of 18 167 982, with 9 110 481 men 
and 87.4% rural inhabitants.12
Since 2005, the Amhara referral hospitals have been 
providing free ART services as part of the National AIDS 
Control Programme. The hospitals provide clinical care, 
including laboratory and pharmacy services.
study participants
The inclusion criteria for the children were aged below 
15 years, initiation into ART and follow-up of at least 6 
months, plus availability of required information such as 
age, CD4 count and at least two visits after the initiation 
of ART. Of 11 865 registered children, 824 were included 
in the study.
sample size and sampling technique
The sample size was calculated based on a log-rank test 
with the assumption of the proportional Cox hazard 
model.20 In a previous study, chronic diarrhoea after 
initiation of ART was taken as a significant predictor of 
failure, with an HR of 3.44.18 An assumption of signifi-
cance level α=0.05 (z
α/2=1.96) and power 1-β=0.8 (zβ=0.84) 
were considered. Additionally, a 10% difference in favour 
of lost to follow-up (incomplete information) was consid-
ered. Finally, a total sample of 824 was obtained.
A systematic random sampling technique was used to 
select the participants. The sample size was proportion-
ally allocated to each randomly selected hospital in order 
to obtain fair or proportional size of study participants in 
all hospitals for the sake of representativeness.
data collection tools and procedures
A structured data abstraction checklist was adopted from 
the HIV care/ART intake forms of the Federal Ministry 
of Health of Ethiopia.3 Training was given to data collec-
tors on how to review registration logbooks and medical 
charts and maintain confidentiality of the data. ART 
nurses working in the ART clinics were recruited as data 
collectors.
The primary outcome was treatment failure, defined 
as clinical or immunological failure. We used the stan-
dard definition of clinical failure as occurrences of new 
opportunistic infections (OIs) or malignancies, or failure 
to sustain growth rate in a child who had responded 
initially, or loss of neurodevelopmental milestones having 
excluded other causes like inadequate nutrition and 
tuberculosis (TB) after 6 months of effective treatment. 
Immunological failure was also defined according to 
the national guidelines. That is, a child younger than 5 
years should have persistent CD4 levels below 200 cells/
mm3 or <10%, and a child older than 5 years should 
have persistent CD4 levels below 100 cells/mm3. Virolog-
ical criteria were not used because of the complexity of 
defining ART failure in children using viral load and the 
unavailability of regular virological tests in Ethiopia.3 21 
In addition, all other outcomes such as death and lost to 
follow-up are defined as censored events, unless there 
is a clear indication of treatment failure. Time to the 
first occurrence of any of these outcomes was calculated 
by subtracting the date of Highly active antiretroviral 
therapy (HAART) regimen initiation from the date the 
event occurred.
Several studies have shown that there is no perfect way 
to measure adherence; however, it can be assessed at each 
visit through ARV pill count or pharmacy records, and 
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missed or late clinic visits in resource-poor countries.21–24 
In Ethiopia, during all HIV clinic visits, the healthcare 
provider assesses adherence to ART by pill counts at visits 
and records adherence appropriately as ‘GOOD’ (≥95% 
adherence) or FAIR (80%–95%), while POOR adherence 
is less than 80%.21 Thus adherence to ART was assessed 
using retrospective records review. Missing doses in the 
last 3 days or missing >15 doses since last visit was defined 
as poor adherence.
We also extracted data on sociodemographic character-
istics (age and sex), clinical characteristics (WHO clinical 
staging, CD4 count at initiation of ART, change in weight, 
presence of OIs and calendar year of starting ART) and 
treatment-related factors (drug regimen, OI prophylaxis, 
history of first-line modification, treatment duration and 
drug side effects).
data processing and analysis
The data were checked for inconsistencies, coding errors, 
completeness, accuracy, clarity and missing values before 
they were entered. The data were entered using Epi Info 
V.7 and then exported to R V.3.2.0 statistical software for 
further data cleaning and statistical analysis.
Summary measures such as counts, percentages, 
medians, IQRs, means and SD were computed. A Kaplan-
Meier curve method and log-rank test were applied to 
estimate the probability of treatment failure at a given 
time and to compare survival probability between cate-
gorical variables, respectively.
The assumptions of log-rank test and proportional 
hazards (ie, probability of treatment failure occurring 
at any time point is the same for each population) were 
checked25 using graphical and statistical tests for time to 
treatment failure and to identify the potential predictors.
Weibull and exponential models were used to identify 
the predictors of treatment failure by considering hetero-
geneity between hospitals, and hence frailty model was 
also used.26 27 The factors significantly associated with 
first-line ART failure in the univariate models at P value 
less than 0.2 were included in the multivariable survival 
model and were further examined in frailty models. A 
default enter selection procedure was used to adjust 
models, with a variable being included in the model 
fitted. A more parsimonious hazard model was chosen by 
means of the likelihood ratio test and Akaike information 
criterion (AIC). The proportional hazard model assump-
tion was tested.
results
baseline characteristics
A total of 1006 samples were screened, of which 52 (5.2%) 
were excluded following the inclusion criteria. However, 
130 (13.6%) were further excluded because of incom-
plete recording. Finally, a total of 824 children were 
included in the analysis. More than half (445, 54.1%) 
were female. The mean (±SD) age at initiation of ART 
and the average duration of follow-up were 6.4±3.6 years 
and 34.7±21.3 months, respectively. About 34 (4.15%) of 
the participants had history of use of PMTCT (preven-
tion of maternal to child transmission) service. Of whom, 
8 (23.5%) received only nevirapine (NVP) ARV during 
PMTCT, whereas 37.50% received both NVP and zidovu-
dine (AZT). At initiation of treatment, 294 (35.8%) were 
in WHO clinical stages III and IV. Majority  (588, 71.5%) 
of the children were initiated with NVP-based regimen 
with d4T-3TC-NVP and AZT-3TC-NVP, whereas efavirenz-
based regimens were used in 218 (26.5%) of the patients. 
More than half (62.6%) had CD4 count above 350 cells/
mm3.
The median z-scores for weight and height were −1.53 
(IQR: −2.49 to –0.25) and −0.77 (IQR: −2.36 to 0.09), 
respectively. During the initiation of ART, 218 (26.4%) 
had OIs. The most common OIs were unexplained 
persistent diarrhoea (>14 days) (14.2%), followed by 
pulmonary TB (13.3%). After the initiation of ART, 99 
(12.0%) of the children developed OIs. During follow-up, 
the main (17.2%) OI was pulmonary TB. On the level 
of treatment adherence, 447 (54.9%) had good adher-
ence (>95%). Furthermore, the overall full disclosure 
status (age 7 years and older) of HIV to children was 182 
(22.1%) (table 1).
treatment failure
Children were followed for a minimum of 6 and 
a maximum of 77.83 months. The median (IQR) follow-up 
period was 30.5 months (14.6–51.4 months). The total 
person time observation was 28 562.5 person-months.
A total of 63 (7.7%) children developed treatment 
failure. Of these, 17 (27.0%) failures were reported 
within the first 24 months of follow-up. Of the failures, 17 
(27.0%) were immunological and 46 (73.0%) were clin-
ical failures. Only 15 (23.8%) children were switched 
to second-line drugs after first-line treatment failure, 
confirmed by virological failure (plasma viral load above 
1000 copies/mL). At the time of establishing treatment 
failure, all the children had been on ART for at least 6 
months.
The main reasons for modifying the baseline drug 
regimen for 299 (36.3%) of the children were drug 
stockout, drug side effects, clinical failure and new TB 
case for 145 (54.3), 72 (27.0%), 24 (9.0%) and 8 (3.0%), 
respectively (figure 1).
The incidence of treatment failure during first-line 
regimen was 22.1 (95% CI 17.2 to 28.2) per 10 000 person-
months of observation. The incidence of immunological 
failure was 5.96 (95% CI 37 to 9.6) per 10 000 person-
months and clinical failure was 16.1 (95% CI 12.1 to 21.5) 
per 10 000 person-months. The cumulative probabilities 
of failure at 20, 40, 60 and 80 months were 0.02, 0.06, 0.15 
and 0.43, respectively (figure 2).
Both the estimated survival curve and the log-rank 
tests showed that there was no overall difference 
among the survival curves of the hospitals (log-rank 
χ2(5)=7, P=0.2). According to the log-rank test, sex of 
the child (χ2(1)=4.15, P >χ2=0.042), disclosurGe status 
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(χ2(1)=5.12, P >χ2=0.024), year of initiation (χ2(1)=41.38, 
P >χ2=0.0000), initial regimen code (χ2(3)=9.09, 
P >χ2=0.0281) and duration of follow-up (χ2(1)=63.20, 
P >χ2<0.0001) indicated statistically significant differ-
ences of survival curve observed among groups (figures 3 
and 4).
Predictors of treatment failure
Before we fit the final model, we assessed the model 
adequacy and chose the most parsimonious model. 
According to Schoenfeld global test, the overall full 
model satisfies the proportional hazard assumption 
(χ2(11)=4.44, P >χ=0.9554).
Based on AIC, the Weibull (AIC=343.1636) model was 
more efficient than Cox proportional hazard (AIC=651.5), 
parametric exponential model (AIC=440.5) and frailty 
models (table 2). Thus, the inclusion of a frailty effect 
estimated a not statistically significant variance and indi-
cates the absence of a heterogeneous or unobserved vari-
ability among hospitals (table 2).
In the univariate Weibull proportional hazard model 
fitted, sex of children, disclosure of HIV status of the 
child, duration of follow-up, initial regimen initiation, 
baseline CD4 count, drug substitutions, weight for age 
z-score, adherence, baseline OI occurrence and calendar 
year of treatment initiations were significant at a P value 
less than 0.2. In the multivariable models, the covariate 
not disclosing their HIV status, baseline OI presence and 
long duration of follow-up in months were predictors of 
the time to treatment failure of the first-line regimen at 
the 5% significance level. The HR for the presence of OIs 
during initiations of ART was 2.3 times higher than the 
hazard for the absence of OIs (adjusted HR (AHR)=2.3, 
95% CI 1.3 to 4.0). Similarly the hazard of children who 
did not disclose their HIV status was 4.5 times higher than 
those who disclosed their HIV status (AHR=4.5, 95% CI 
1.8 to 11.5). Holding the other covariates constant, chil-
dren who had less duration of follow-up in months had 
significantly high difference to fail the treatment. Thus, 
those who followed up for more than 34 months were 
94% less likely to develop treatment failure compared 
with those whose follow-up time was less than or equal to 
34 months (AHR=0.06, 95% CI 0.02 to 0.19) at any time 
(table 3). 
disCussiOn
This study investigated the incidence and risk factors of 
treatment failure to first-line regimen among HIV-infected 
children (<15 years of age) in Amhara National Regional 
State hospitals in north-west Ethiopia. In this study 7.7% 
treatment failure and 22.1/10 000 person-months were 
observed. None disclosed HIV status to the child, the 
presence of baseline OIs and ART follow-up of more than 
35 months were predictors of treatment failure.
In the study, the incidence of treatment failure was 
7.7% (95% CI 5.83% to 9.46%); clinical and immuno-
logical failure accounted for 27% and 73%, respectively. 
In all hospitals, only 15 (23.8%) children switched to a 
second-line regimen. This finding was lower than that 
of a study done in Addis Ababa (14.1%)18 and Adama 
Table 1 Sociodemographic, clinical and immunological 
characteristics of HIV-positive children on first-line HAART in 
public hospitals in north-west Ethiopia, January 2010–March 
2016
Variable Category Frequency (n) %
Age <5 283 34.68
5–9 347 42.52
≥10 186 22.79
Sex Female 445 54.07
Male 378 45.93
WHO clinical stage at 
initiation
T stage I 257 31.19
T stage II 273 33.13
T stage III 238 28.88
T stage IV 56 6.80
Baseline CD4 
count (cells/mm3) 
<200 145 17.60
200–350 166 20.14
351–500 323 39.20
≥500 190 23.06
Duration of follow-up in 
months
≤34 448 54.57
≥35 373 45.43
Weight to age z-score <−2 SD 327 40.42
−2 SD to 2 SD 423 52.29
>2 SD 59 7.29
Height to age z-score <−2 SD 245 29.91
−2 SD to 2 SD 469 57.26
>2 SD 105 12.82
Adherence Poor (<95%) 368 45.15
Good (≥95%) 447 54.85
Year of initiations 2010–2012 443 53.76
2013–2016 381 46.24
Last status Alive 640 77.67
Die 17 2.06
Lost to follow-up 27 3.28
Transfer to 125 15.17
Switch to second-
line
15 1.82
Baseline NNRTI 
regimen
EFV 588 71.36
NVP 218 26.46
LPV/r 12 1.46
ABC+3TC+AZT 6 0.73
Side effects No 755 91.63
Yes 69 8.37
Baseline opportunistic 
infections
No 606 73.54
Yes 218 26.46
3TC, Lamivudine; ABC, Abacavir; AZT, zidovudine; EFV, efavirenz; 
HAART, Highly active antiretroviral therapy; NNRTI, Non-nucleoside 
reverse transcriptase inhibitor; NVP, nevirapine; LPV/r, Lopinavir/
ritonavir. 
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regional hospital (69.8%).19 Moreover, this study showed 
a lower failure rate than other studies done in Africa, for 
example Nigeria (18.8%),13 Uganda (34%),28 a combined 
study from Mozambique-Uganda (29%)16 and Cambodia 
(8.6%).29 However, the result was higher than the result 
in India of 5.1%.30 This may be due to improvements of 
healthcare services in the later periods of follow-up as 
compared with earlier periods. This means that there is a 
general consensus, in which countries encourage earlier 
HIV diagnosis and earlier antiretroviral treatment, and 
promote the use of less toxic regimens and more stra-
tegic laboratory monitoring. Furthermore, new evidence 
has also emerged on when to initiate ART, optimal ART 
regimens, the management of HIV coinfection and the 
Figure 3 Survival probability plot by sex of follow-up for 
HIV-positive children on first-line antiretroviral therapy at 
public hospitals in north-west Ethiopia, January 2010–March 
2016.
Figure 1 Reasons of drug modification among children’s first-line antiretroviral therapy regimen at public hospitals 
in north-west Ethiopia, January 2010–March 2016. Keys: baseline drug modification:  clinical failure;  new 
drug;  drug side effects;  drug stockout;   new tuberculosis (TB) case;  virological failure; 
 immunological failure;   no change in baseline drug;  others (such as risk of pregnancy, switch to second-
line). 
Figure 2 Kaplan-Meier survival curve showing the 
probability of treatment failure of HIV-positive children 
on first-line antiretroviral therapy at public hospitals in 
north-west Ethiopia, January 2010–March 2016. Key: 
 probability of failure of the first-line drug. 
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management of ART failure. Additionally, this may be 
explained by differences in sociodemographic charac-
teristics, stage of the disease when ART was initiated 
and adherence of children, which readily affect the 
response to and effectiveness of ART. Another expla-
nation may be differences in the diagnostic criteria for 
treatment failure. Hence the above-reported studies 
were assessed using viral load, which can diagnose treat-
ment failure early and can overestimate the amount as 
compared with clinical and immunological indicators.
The crude incidence rate was 22.06 (95% CI 17.23 to 
28.24) per 10 000 person-months of observation, which 
was lower than the finding of the combined cohort study 
in Mozambique and Uganda, which reported 20.0 events 
per 100 person-years (95% CI 17.5 to 22.9).16 Because 
most failures occur soon after initiation of therapy, a 
shorter follow-up period is likely to find a higher proba-
bility of failure when compared with a study with a longer 
follow-up period. The difference might be due to the vari-
ations in the study area and the higher number of failures 
in comparison with our study.
In our study, children who did not disclose their HIV 
status were more likely to experience treatment failure 
than those who did. This might be due to the fact that 
disclosure tended to reduce anxiety and improve adher-
ence in children.3 Only 22.1% of children knew their status, 
which is lower than the result of a cross-sectional study 
done at the University of Gondar (39.5%).31 This could 
be explained by differences in study designs. However, it 
is higher than that of a study conducted in Addis Ababa 
(17.4%).32 This might be due to the increase in awareness, 
adequate support and acceptance of people living with 
HIV in Addis Ababa than in the Amhara Region.
The proportion of children with treatment failure was 
significantly higher in the first 34 months of HAART 
follow-up than in the last ones. This was in contrast with 
the finding of a study done in Addis Ababa.32 Our study 
revealed 5 (3.45%) failures in the first 12 months and 
21 failures (8.64%) in the last year of study. This was 
because the ART service provided before the universal 
increase of access to treatment for all children living 
with HIV was limited.3
The rate of OIs (26.46%) was higher than the rate 
of a study done in Addis Ababa (3.5%),18 which noted 
the common OIs were unexplained persistent diar-
rhoea (>14 days) (14.22%), followed by pulmonary TB 
(13.3%), severe recurrent pneumonia (11.47%), unex-
plained persistent ear discharge (12.39%), herpes zoster 
(10.55%) and unexplained persistent fever (≥30 days) 
(5.96%). However, this was lower than the finding of a 
study conducted in India, which reported 40%–49.7%.30 
Additionally, having advanced opportunistic disease may 
compromise immunity, and this may negatively affect 
response to treatment.
This study showed that the baseline CD4 count was not 
a predictor of treatment failure. This was in contrast with 
the result of studies done in Addis Ababa,18 Cambodia29 
and Thailand,33 but consistent with the study conducted 
among Ugandan children.28 This might be due to the high 
public health advocated approach to ART nowadays, 
which substantially increased the awareness of health-
care providers and caregivers. In fact, patients with a very 
low CD4 count are more likely to have different OIs, and 
the added burden of these diseases further complicates 
their treatment response. Additionally, this needs further 
exploration of changes in CD4 cell count using consecu-
tive measurements.
Figure 4 Survival probability plot by duration of follow-up 
for HIV-positive children on first-line antiretroviral therapy 
(ART) at public hospitals in north-west Ethiopia, January 
2010–March 2016.
Table 2 Summary of model comparison between semi-Cox proportional hazard models and parametric Cox regression 
models using AIC and other estimates
Parameter
Proportional 
hazard Weibull Exponential
Frailty
Exponential Weibull
Gamma Gamma
–2 log L −289.0 −154.9 −205.4 −206.7 −154.9
AIC 602.0 339.7 438.9 443.4 341.7
BIC 658.2 409.9 504.4 513.7 416.6
LR χ2
(P value)
96.2
(<0.0001)
79.7
(<0.0001)
24.8
(0.0248)
27.8
(0.001)
84.7
(<0.0001)
AIC, Akaike information criterion; BIC, Bayesian information criterion; LR, likelihood ratio.
group.bmj.com on April 9, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
7Sisay MM, et al. BMJ Open 2018;8:e019181. doi:10.1136/bmjopen-2017-019181
Open Access
The possible limitation of the study is that the data 
were collected from routine medical care records, 
which were limited in terms of information on possible 
key predictors of failures, such as PMTCT and labo-
ratory assessments. Adherence was measured by pill 
count at last visit, even though the nature of the 
study design allowed for multiple measurements. It 
is because measurements abstracted from charts were 
performed by different clinicians, some of whom do 
not adhere to the same rigorous quality control 
standards as the guideline. In Ethiopia, as in other 
low-income countries, the identification of treatment 
failure mainly depends on clinical and immunolog-
ical criteria for the routine monitoring of patients on 
first-line ART. Therefore, we were unable to explore 
the virological failure that might have underestimated 
Table 3 Multivariable analysis using the Weibull Cox regression model for predictors of first-line ART failure of HIV-positive 
children at public hospitals in north-west Ethiopia, January 2010–March 2016
Variables
Survival status Incidence 
density/10 000 Crude HR (95% CI) Adjusted HR (95% CI)Censored Event
Sex of child
  Male 357 22 17 1
  Female 404 41 27 1.63 (0.97 to 2.74) *
Disclosure status
  No 586 56 25 2.35 (1.07 to 5.16) 4.51 (1.78 to 11.45)
  Yes 175 7 11 1 1
Duration of follow-up in months
  ≤34 424 25 32 1 1
  ≥35 337 38 18 0.05 (0.02 to 0.10) 0.06 (0.02 to 0.19)
Baseline OIs
  No 567 39 19 1 1
  Yes 194 24 30 1.47 (0.88 to 2.44) 2.27 (1.29 to 3.99)
Baseline CD4 count, cells/mm3
  <200 130 15 27 1.45 (0.66 to 3.15) *
  200–350 158 8 15 0.88 (0.35 to 2.19) *
  351–500 294 29 26 1.41 (0.71 to 2.83)
  ≥500 179 11 18 1
Baseline NNRTI regimen
  NVP 544 44 20 1
  EFV 202 16 26 1.54 (0.87 to 2.72) *
  LVP/r 15 3 62 4.33 (1.34 to 13.99) *
Year of initiations
  ≤2013 402 41 19 1
  ≥2014 359 22 30 7.33 (3.74 to 14.36) *
Weight for age z-score
  <−2 SD 295 32 25 0.49 (0.17 to 1.40) *
  −2 SD to 2 SD 408 27 19 0.38 (0.13 to 1.11) *
  >2 SD 58 4 29 1
Adherence
  Poor (<95%) 349 28 21 0.98 (0.60 to 1.63) *
  Good (≥95%) 412 35 23 1
Drug substitutions
  No 494 31 22 1.44 (0.87 to 2.38) *
  Yes 267 32 22 1
*Non-significant from the Weibull Cox regression model at 5% level of significance.
ART, antiretroviral therapy; EFV, efavirenz; LPV/r, Lopinavir; NNRTI, Non-nucleoside reverse transcriptase inhibitor; NVP, nevirapine; 
OIs, opportunistic infections. 
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the treatment failure. In Ethiopia, access to ART is 
expanding to all patients including children, and in 
this country HIV/AIDS care and treatment are carried 
out based on a guideline called the ‘National Guide-
lines for Comprehensive HIV Prevention, Care And 
Treatment’. This study was carried out in Amhara 
Region hospitals, which provide services based on the 
above guidelines to patients coming from every corner 
of the region specifically and nationally in general, so 
this study can be generalised to the larger population 
since we have taken adequate sample size and strong 
study design. Therefore these findings may be gener-
alisable topatients with treatment experience. Since 
our patients participated in a large multicentre study 
within the region and country, their experiences may 
not differ from that of patients accessing treatment in 
the remaining community-based setting because all 
hospitals follow the same guidelines and support. 
Future studies should be conducted to evaluate the 
best approaches to use HIV-RNA monitoring.
In conclusion, the incidence of treatment failure 
remains a significant public health concern in Ethi-
opia. Undisclosed HIV status of child, presence of OIs 
during initiation of ART and prolonged follow-up were 
found to be the predictors of treatment failure. Early 
detection of treatment failure is important for optimal 
management of HIV-infected patients receiving ART. 
Furthermore, future studies can examine underlying 
relevant factors, including repeat measurements such 
as CD4 count, for treatment failure.
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